Reports of the results of electrophysiologic testing of antiarrhythmic regimens have concentrated on inducibility of ventricular tachycardias during drug treatment. Many drug regimens, however, affect the tachycardia but fail to prevent its initiation. In this study, 258 patients who underwent serial e1ectrophysiologic studies were followed up. The patients were divided into three groups on the basis of the results of electrophysiologic testing. Group 1 included patients in whom the initiation of ventricular tachycardia was prevented by the drug regimen. In groups 2 and 3 the ventricular tachycardia was still inducible with the discharge drug regimen. In group 2, the drug regimen demonstrated a beneficial response (that is, the tachycardia cycle length increased by > 100 ms and the tachycardia did not produce severe symptoms). In group 3, the regimen did not produce a beneficial response.
The ability to prevent the initiation of a sustained ventricular tachyarrhythmia by programmed stimulation has been shown to predict antiarrhythmic drug efficacy. The inability to prevent the initiation of sustained ventricular tachycardia, on the other hand, is not always associated with a poor clinical outcome. Previous reports (1-13) of the results of electrophysiologic testing have highlighted the concepts of inducibility and noninducibility (1-9), the number of induced ventricular complexes (10, II) , the ease of tachycardia induction (I, II) or the presence or absence of repetitive ventricular forms in response to programmed stimulation (10) (11) (12) (13) During follow-up, recurrence of sustained ventricular tachycardia occurred in 7 (7%) of 103 group 1 patients but in 20 (39%) of 51 and 52 (50%) of 104 group 2 and 3 patients, respectively. However, the total mortality and sudden death mortality rates were substantially reduced in group 2 (12 and 4%, respectively) compared with group 3 (39 and 34%). In fact, the total mortality and sudden death mortality in groups 1 and 2 were not significantly different. Thus, under certain circumstances, a drug regimen that produces a beneficial response may be an acceptable clinical alternative, particularly when no regimen prevents induction of ventricular tachycardia.
(J Am Coil CardioI1987; 10:83-9) as predictors of the clinical efficacy of a particular drug regimen. The present study examined patients whose arrhythmias remained inducible at electrophysiologic study to determine if a defined "improvement" in the characteristics of the induced ventricular tachycardia could predict arrhythmia recurrence or patient survival, or both.
Methods
Study patients. The initial patient group comprised 291 consecutive patients who were referred for electrophysiologic evaluation in whom sustained ventricular tachycardia or ventricular fibrillation was induced during a baseline study. Twelve of these patients were treated surgically immediately after drug therapy evaluation and were therefore excluded from study. All other patients had at least one drug followup study before discharge. Sixteen patients were discharged on an antiarrhythmic regimen not tested at follow-up study and were also excluded from study. One patient was ex- c1uded because catheter manipulation initiated ventricular tachyc ardia both in the baselin e and in the follow-up studie s. Two patient s refused follow-up study before selection of an effective medical regimen and two were lost to follow-up after hospital discharge. The final study group compri sed 258 patient s. The patients ranged in age from 15 to 86 years (mean 61). Of the 210 (81%) who had coronary artery diseas e , 205 (98%) had sustained a previous myocardial infarcti on . Nineteen of these infarctions had taken place < 6 weeks before the time of initial evaluation . The remaining patient s had a variety of heart diseases ( Table I) . Ejection fraction ranged from 7 to 83% (mean 29%).
Indications for electrophys iologic study included recurrent sustained ventricular tach ycardia (145 patients), syncope of unkn own origin (43 patients), symptomatic nonsustained ventricular tachycardia (35 patients), out of hospital cardiac arrest (33 patients) and tachycardia or palpitation of unkno wn origin (2 patients). Before electroph ysiologic testing, patient s had under gone zero to six emp iric drug trials that were unsucce ssful becau se of intolerance or ineffectivene ss .
Electrophysiologic study. Written informed consent was obtained from each patient before study. Electrophysiologic studies were completed at baseline in a postabsorpti ve state with light diazepam sedation after all antiarrh ythmic medication s had been discontinued for a minimum of five halflives. Beta-adrenergic blocking agents, digitalis glycosides and calcium channel blockers were continued throughout electroph ysiologic testing if administered for nonarrh ythmic indications.
Multiple electrode catheters were inserted percutaneously under local bupivacaine (0 .25%) anesthesia and were positioned with fluoroscopic guidance . Surface electrocardiographic (ECG) leads I, aVF and V I and intracardiac electrograms were displayed on an oscilloscope (Electronics for Medicine VR 16) and were recorded on magnetic analog tape . Real-time recordings at paper speeds of 100 to 250 mm/s were obta ined using an ink jet record er (SiemensElema mingograf) .
Programmed ventricular stimulation included the introducti on of single, double and triple extra stimuli from the right ventricular apex durin g normal sinus rhythm and ventricular pacing at cycle lengths of 600 and 450 ms. The stimulation protocol was repeated at the right ventricular outflow tract if no sustained arrhythmia was induced at the apex . Left ventricular stimulation at two sites was performed in patients with documented sustained ventricular tachycardia or previous cardiac arrest if no arrhythmias could be initiated by right ventricular stimulation. When the morphology and rate of the clinical arrhythmia were available, they were correlated with those characteristics of the induced arrhythmias and assessment s were made on the clinical arrhythmias.
The complete stimulation protocol was repeated at both right ventricular sites at follow-up studies unless a sustained arrhythmia was initiated reproducibly before completion of the protocol. A single induction was accepted if cardi oversion was required for arrhythmia termination. Left ventricular stimulation was performed only in patients in whom it had been required for arrhythmia initiation in the baseline study.
Serial electrophysiologic testing in all pati ents proceeded with the intention of eliminating inducible ventricular tach ycardia or fibrillation. A patient was discharged on a regimen that did not prevent initiation of ventricular tachycardia or fibrillation only after failure of all applicable regim ens.
Definitions. Sustained ventricular tachycardia was defined as ventricular tachycardi a of ::::30 seconds' duration or requiring termination before 30 seconds because of hemodynamic intolerance.
ventricular fibrillati on was defined as the initiated arrhythmia jf within 3 seconds after initiation of a sustained ventricular tachyarrhythmia, typical ventricular fibrillation was present in any surface ECG \cad .
Nonsustained ventricular tachycardia was defined as spontaneously terminating ventricular tachycardia lastin g longer than six complexes but < 30 seconds.
Noninducible was defined as fewer than 16 complexes of ventricular tachycardia initiated using the complete stimulation protocol.
Severe symptoms during ventricular tachycardia included syncope, near syncope, dizziness, angina or dyspnea . Mild symptoms durin g ventricular tachycardia included only palpitation.
A " beneficial response" on antiarrhythmic therapy was prospectively defined as inducible sustained ventricular tachycardia at follow-up study with an increase in cycle length of :::: 100 ms comp ared with baseline and the absence of seve re symptoms durin g the induced tachycardia. If the originally induced arrhythmia was ventricular fibrillation , a beneficial respon se at follow-up study was considered to be inducible sustained ventricular tachycardia with a cycle length of ::::300 ms that was not associa ted with severe symptoms. Term ination of ventricular tachycardia had to be accomplished with programmed stimulation or overdrive pacing for a beneficial response to be present.
Sudden death was defined as an unexpected witnessed death occurring within I hour of the onset of symptoms representing a catas trophic change in the state of hea lth not otherwise explained by obviou s eve nts. If the dea th was not witne ssed , it was considered sudden if the patient was see n within the prior 12 hours and had been free of chest pain and other significant symptoms and if the patient's overall clinical status had been stable. If a patient was successfully resu scitated from an arrhythmic event (out of hospital cardiac arrest), that event was considered a sudden cardiac dea th for statistical purposes. Follow-up. Antiarrhythmic medications used in this study are tab ulated in Table 2 . Patient s were followed up in a research arrhyth mia cl inic if they were taki ng an investigational drug or by their private phy sician if they were taking conv entional agen ts. Follow-up data were also obtained through telephone con tact with patients or their physician s and through yearly questionnaires. All deaths were investigated using medical or hospital records, interviews with observers and pos tmortem findings when they were available. Symptomatic episode s co nsistent with recurrent arrhythmia were investigated with Holter ECG monitoring, transtelephonic ECG transmissions or in-hospital telemetric monitoring , or all three .
The duration offollow-up was calculated from the date
cf electrophysiologic study to each of three clinical end points: I) arrhythmia recurrence, 2) sudden cardiac death, and 3) deat h from any caus e (total mortality) . When modifications in antiarrhythmic therapy were made, patients were censored as of the date of change in their medication . If a medication was discontin ued because of intolerable side effec ts, the patient was censored on the date the dru g was discontinued . If death occurred without a doc umented recurrence (death from nonarrhythmic causes), the patie nt was censored on the date of death . In analyzing recurrences , patients who died suddenly were considered to have had recurrence on the date of death . Th e most recent clinic visit before Apri l 29. 1986 was the analy sis end point for tho se patients who did not reach other end points . Life table ana lysis was applied to each of the three clinical end point s and duced (group I) and 155 had inducible sustained ventricular tachycardia . Fifty-one of the latter patient s (group 2) demonstrated a " beneficial respon se" ; the rem aining I04 (group 3) did not meet criteria for a beneficial respon se . Fort y-five of the group 3 patients had onl y mild symptoms durin g ventricular tach ycardia at follow-up study but the tach ycardia cycle length increa sed by < 100 ms. Thirteen patients had an increase in tachycard ia cycle length of 2: 100 ms but had severe symptoms durin g ventricular tach ycardia. Fortyfive patients failed to show an increase in ve ntricular tachycardia cycle length of 100 ms and had severe symptoms during induced ventricular tachy cardia. One patient had a ventr icular tachycardia cycle length increase of 110 ms and had mild symptoms during ventricular tachycardia, but cardioversion was required for term ination . Table 3 . In patients who had inducible sustained ventri cul ar tachycardia at follow -up study (gro ups 2 and 3), no differences were noted in age , sex, left ventricular ejection fraction , incidence of coronary artery disease or ventricular tach ycardia cycle length observed at baseline study. There was no difference in the proport ion of patients in whom seve re symptoms were produ ced by arrhythmia during the baseline study among the gro ups (group I = 94% ; group 2 = 94%; group 3 = 92%).
Clinical variables of the three groups are compared in
Arrhythmia recurrence and mortality. Using arrh ythmia recurrence as a clinical end point , the recurrence-free interval was not significantly different between groups 2 and 3. Arrhythmias recurred in 32% of group 2 and 35% of group 3 patient s within I year and in 39 and 53 % , respectively, within 2 years of follow-up. Group I, however , had significantly lower recurrence rates at I and 2 year followup (4 and 6%, respectively) (Fig. I, Table 4) . Life tabl e analysis demonstrated a significant difference between group I and groups 2 and 3 (p < 0 .0001) . or ventricular fibrillat ion (n = 37) at the baseline electrophysiologi c study. At baseline , the arrhythmia produ ced severe symptoms in 241 patient s and mild symptoms in 17. In the 241 patients with severe symptoms , 221 had syncope or near syncope and the remainder had angina or dyspnea.
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Follow-up electrophysiologic studies. At follow-up study, 103 patients did not have sustained arrhythmia in- recurrences during the follow-up period; in group 3, in which no beneficial response was achieved, 52 (50%) of 104 patients had recurrent arrhythmias. Six patients (12%) in group 2 died and 2 of these deaths (4%) were sudden, whereas 41 patients (39%) in group 3 died and 35 of these deaths (34%) were sudden. Individual criteria of the beneficial response. To evaluate each variable in the "beneficial response" definition, symptoms during ventricular tachycardia as well as the change in ventricular tachycardia cycle length were examined individually. Of 97 patients who had only mild symptoms during induced ventricular tachycardia at follow-up study, 46 (47%) had a recurrence, 25 (26%) died and sudden death occurred in 19 (20%). Thirteen patients had severe symptoms during induced ventricular tachycardia despite having an increase in tachycardia cycle length of 2: 100 ms; six (46%) of these patients died, five suddenly. To determine whether ventricular tachycardia cycle length at follow-up study alone could predict a favorable outcome (independent of symptoms during ventricular tachycardia), two additional patient groups were examined. Fifty patients had a ventricular tachycardia cycle length of 2:400 ms at follow-up study; sustained arrhythmia occurred in 23 (46%) and sudden death occurred in 7 (14%). Twenty-four patients had a ventricular tachycardia cycle length of 2:450 ms at follow-up study; 12 (50%) had a recurrence and 3 (13%) died suddenly ( Table   4) .
No differences were noted between patients taking amiodarone and those receiving other therapy in arrhythmia recurrence, total mortality or sudden death.
Discussion
Role of electrophysiologic testing. It has been previously demonstrated ( 1-15) that electrophysiologic testing is useful in identifying patients at risk of recurrent ventricular tachycardia or ventricular fibrillation, or both, and that the results of programmed stimulation may be predictive of the response to antiarrhythmic therapy. In this study we identified a group of patients with persistent vulnerability to inducible sustained ventricular tachyarrhythmias in whom the clinical outcome with respect to mortality and particularly sudden death resembles the course of patients in whom arrhythmia induction is prevented by drug therapy. Although the incidence of arrhythmia recurrence in this investigation did not differ between groups showing a beneficial response to antiarrhythmic therapyand those not showing this response, total mortality and the incidence of sudden death did differ significantly. This suggests that arrhythmia recurrence is more often a nonfatal event in patients demonstrating a beneficial response.
Arrhythmia recurrence and mortality on follow-up. Among patients who continued to have inducible arrhythmia 
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". When total mortality was the statistical end point, there was a significant difference between groups 2 and 3 ( Fig. 2) (p < 0.002). The incidence of sudden cardiac death was also significantly different between groups 2 and 3 (p < 0.0003) (Fig. 3) . There was no difference in either total mortality or sudden cardiac death between patients who no longer had inducible arrhythmia (group I) and those who demonstrated a beneficialresponse to antiarrhythmic therapy (group 2).
The clinical end pointsfor the duration ofthe entire study period are summarized in Table 4 Role of increased cycle length versus symptomatic response. The effect of an increase in induced ventricular tachycardia cycle length, independent of symptoms produced during ventricular tachycardia, was not as striking in its influence on total mortality and sudden death events. Patients who had a~1()() ms increase in ventricular tachycardia cycle length, but who still had severe symptoms during ventricular tachycardia, had the highest rate of recurrence and their mortality and sudden death event rates were identical to those of the patients who showed no benefit of therapy. Patients who had mild symptoms during induced sustained ventricular tachycardia but did not meet the cycle length criterion fared slightly better than did patients who had no benefit, but the differences were small and not significant. The good clinical outcome observed in patients who demonstrated the beneficial response appeared to require achieving both criteria of the response.
Limitations of study. This study has several limitations .
The amiodarone group was large although comparisons of amiodarone-treated patients with those not taking amiodarone did not demonstrate significant differences. Regimens that demonstrated a beneficial response were not used on a long-term basis in some patients because amiodarone was usually the last drug tested in an attempt to establish a regimen that prevented initiation of ventricular tachycardia. In these patients amiodarone was often used on a long-term basis. If amiodarone produced a beneficial response it was continued even though a beneficial response was observed with a previously tested regimen. If amiodarone failed to produce a beneficial response and another regimen did achieve this result, the latter regimen was used on a long-term basis. This study was a retrospective analysis of data, although criteria for improvement or beneficial response Were selected prospectively, before review and analysis.
Reduction in total mortality. Most investigators (1-15) have reported the recurrence or sudden death rate, or both, but not total mortality in patients in studies similar to ours. It is thus interesting to note that total mortality is also significantly reduced in patients in whom ventricular tachycardia induction is prevented by drug therapy. This study also extends the follow-up experience with regimens selected for treatment of ventricular tachycardia to periods of > 3 years. This study substantiates that regimens identified as effective remain protective for several years.
Factors that determine the symptoms and clinical impact of ventricular tachyarrhythmias. This study raises several interesting and interrelated questions: why should patients with mild symptoms not have a good clinical outcome if the tachycardia cycle length did not increase> 100 ms, and why are cycle length criteria alone not sufficient to identify a beneficial response? This study was not designed to specifically answer these questions; however, some speculation seems appropriate. It is clear that the hemodynamic consequences of a ventricular tachycardia are due to an interaction between the cycle length of the arrhythmia and the underlying cardiac status, but the cycle length appears to be of prime importance (16) (17) (18) . Symptoms such as syncope (16) and cardiac arrest (17) as well as the systolic blood pressure (18) during ventricular tachycardia have been shown to correlate with the cycle length. However, the hemodynamics of ventricular tachycardia are undoubtedly complex and not completely understood (19, 20) . Stability of ventricular tachycardia, ischemia produced by the rapid rate and other factors that may evolve during an episode of arrhythmia, have not been well studied. It appears that the combination of an increase in cycle length and a reduction in symptoms during tachycardia are needed to assure a lessening of the risk of sudden death.
Implications. Analyses of clinical end points of total mortality and sudden death for patients who no longer had inducible arrhythmia at electrophysiologic follow-up study as well as for patients who demonstrated a beneficial response to antiarrhythmic therapy were not significantly different. Thus, patients who demonstrate a benefit of antiarrhythmic therapy at electrophysiologic testing can be expected to have recurrence of ventricular tachycardia at the same rate as that of other patients in whom the arrhythmia remains inducible but these recurrences, will not be life-threatening events in most cases; arrhythmias will likely resemble the arrhythmias induced at follow-up study.
Noninducibility should remain the current reference standard for defining effective antiarrhythmic regimens. Demonstration of a beneficial response with one agent early in the evaluation of an individual patient should not preclude the search for an agent that achieves noninducibility. If prevention of tachycardia induction cannot be achieved, however, a beneficial response may be an acceptable alternative depending on the clinical situation.
Finally, if noninducibility or a beneficial response cannot be demonstrated, alternative therapeutic options should be actively explored. The I, 2 and 3 year mortality rates for this group of patients are very high and alternatives to medical therapy such as antitachycardia devices or surgery may offer benefit for some.
